Revance Therapeutics (RVNC) Reports Complete Enrollment in ASPEN-1 Phase 3 Pivotal Trial for Cervical Dystonia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Trump says Canada's Bombardier must build jets in US or lose market access
- Qualcomm to issue warrant to Amazon for up to 25M shares
- Wall St slips as Gulf tensions send oil to over six-week high
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Revance Therapeutics (RVNC) Tops Q3 EPS by 2c
November 4, 2019 4:38 PM ESTRevance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($0.96), $0.02 better than the analyst estimate of ($0.98).
Revance is entering a pivotal period, given the large number of value-inflection points we have created for the company, beginning in just a few weeks with the anticipated submission of our first BLA for DAXI with the FDA, said Mark J. Foley, President and Chief... More
Revance Therapeutics (RVNC) Reports Publication of SAKURA 1 & SAKURA 2 Results in Plastic and Reconstructive Surgery
November 4, 2019 8:11 AM ESTRevance Therapeutics, Inc. (NASDAQ: RVNC) today announced the publication of results from the Phase 3 studies, SAKURA 1 and SAKURA 2, in Plastic and Reconstructive Surgery (PRS), the peer reviewed Journal of the American Society of Plastic Surgeons. These two Phase 3 studies evaluated Revances long-acting neuromodulator product, DaxibotulinumtoxinA for Injection (DAXI), for the treatment of moderate and severe glabellar lines.
This manuscript presents the findings from SAKURA 1 and 2 side-by-side, which demonstrate the consistency of efficacy and safety results evident between the two pivotal studies, as well as the reproducibility of these... More
